Court Correct In Dismissing Investor Claims Due To Lack Of Scienter, Panel Rules

Mealey's (April 10, 2020, 1:33 PM EDT) -- BOSTON — A federal district court did not err in dismissing federal securities law claims brought against a biopharmaceutical company and certain of its executive officers for allegedly misrepresenting the likelihood...

To view the full article, register now.